Polyurethane-covered Nitinol Strecker stents as primary palliative treatment of malignant biliary obstruction.
OBJECTIVE
To evaluate the clinical efficacy of the polyurethane-covered Nitinol Strecker stent in the treatment of patients with malignant biliary obstruction.


METHODS
Twenty-three covered stents produced by us were placed in 18 patients with malignant biliary obstruction. Jaundice was caused by cholangiocarcinoma (n = 5), pancreatic cancer (n = 6), gallbladder cancer (n = 4), metastatic lymph nodes (n = 2), and tumor of the papilla (n = 1).


RESULTS
The mean patency period of the stents was 37.5 weeks (5-106 weeks). Recurrent obstructive jaundice occurred in two patients (11%). Adequate biliary drainage over 50 weeks or until death was achieved in 17 of 18 patients (94.4%). Late cholangitis was observed in two patients whose stents bridged the ampulla of Vater. Other late severe complications were not encountered.


CONCLUSIONS
Although more study is necessary, our results suggest the clinical efficacy of our covered Nitinol Strecker stent in the management of obstructive jaundice caused by malignant diseases.
Kanasaki
S
S
Department of Radiology, Shiga University of Medical Science, Otsu Shiga, Japan.
Furukawa
A
A
Kane
T
T
Murata
K
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000497:Alloys; D001650:Bile Duct Neoplasms / Q000150:complications; D002779:Cholestasis / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D004867:Equipment Design; D005260:Female; D005706:Gallbladder Neoplasms / Q000150:complications; D006801:Humans; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D011140:Polyurethanes; D015607:Stents; D015996:Survival Rate; D014654:Vascular Patency
D000497:Alloys; D011140:Polyurethanes; C013616:nitinol